Accéder au contenu
Merck

Hepatitis B virus X stimulates redox signaling through activation of ataxia telangiectasia mutated kinase.

International journal of clinical and experimental pathology (2014-06-27)
Yasunobu Matsuda, Ayumi Sanpei, Toshifumi Wakai, Masayuki Kubota, Mami Osawa, Yuki Hirose, Jun Sakata, Takashi Kobayashi, Shun Fujimaki, Masaaki Takamura, Satoshi Yamagiwa, Masahiko Yano, Shogo Ohkoshi, Yutaka Aoyagi
RÉSUMÉ

Hepatitis B virus X (HBX) protein plays a crucial role in carcinogenesis, but its mechanism is unclear. The involvement of ataxia telangiectasia mutated (ATM) kinase in the enhanced redox system was investigated by examining the phosphorylation level of ATM in HBX gene-transfected cells and in transgenic mice following redox system manipulation by treatment with hydrogen peroxide (H2O2) or antioxidant. Western blotting and immunostaining showed that phospho-ATM was significantly increased by HBX both in vitro (3.2-fold; p<0.05) and in vivo (4-fold; p<0.05), and this effect was abrogated by antioxidant treatment. The level of PKC-δ in HBX-expressing cells was increased 3.5-fold compared to controls. Nuclear localized NF-E2-related factor 2 (Nrf2) was increased in HBX-expressing cells exposed to H2O2, but remained at lower levels after the treatment with rottlerin, KU55933, or caffeine. The levels of anti-oxidant molecules were increased in HBX expressing cells and in transgenic mice, indicating that HBX stimulates the Nrf2-mediated redox system. The levels of intracellular reactive oxygen species (ROS) were significantly increased in HBX-expressing cells treated with hydrogen peroxide in the presence of ATM inhibitor KU55933 or caffeine. Treatment of HBX-expressing cells with KU55933 or caffeine before the exposure to H2O2 increased the ratio of cell apoptosis to 33±4% (p<0.05) and 22±4% (p<0.05), respectively. Collectively, HBX stimulates the ATM-mediated PKC-δ/Nrf2 pathway, and maintains the enhanced activity of the redox system. Therefore, manipulating ATM kinase activity might be a useful strategy for treating HBX-induced carcinogenesis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Caféine, anhydrous, 99%, FCC, FG
USP
1,4-Benzoquinone, United States Pharmacopeia (USP) Reference Standard
USP
Caféine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caféine, powder, ReagentPlus®
Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Caféine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
p-Benzoquinone, reagent grade, ≥98%
Supelco
p-Benzoquinone, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caféine, Sigma Reference Standard, vial of 250 mg
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Supelco
Caféine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Caféine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Caféine, meets USP testing specifications, anhydrous
Supelco
Caféine, traceable to primary standards (LGC)
Supelco
p-Benzoquinone, for spectrophotometric det. of amines, ≥99.5% (HPLC)
Sigma-Aldrich
Caféine, BioXtra
Caféine, European Pharmacopoeia (EP) Reference Standard
Caféine, European Pharmacopoeia (EP) Reference Standard